Cargando…
Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
With the advent of targeted therapy for non-small-cell lung cancer, there are many new available treatment options for patients whose cancer harbors an actionable mutation or alteration. These new medications come with numerous side effects, for some of which, the management is not well defined. Ale...
Autores principales: | Seegobin, Karan, Majeed, Umair, Lou, Yanyan, Zhao, Yujie, Manochakian, Rami |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7586266/ https://www.ncbi.nlm.nih.gov/pubmed/33149916 http://dx.doi.org/10.1177/2050313X20966895 |
Ejemplares similares
-
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021) -
Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021) -
First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
por: Majeed, Umair, et al.
Publicado: (2023) -
Alectinib-induced rash unresponsive to desensitization: a case report and literature review
por: Rodriguez, Robin Raquel, et al.
Publicado: (2023) -
Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
por: Majeed, Umair, et al.
Publicado: (2021)